Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.42 |
| ▸ | CMA1 | P23946 | 7/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30852860 | 0.92 | CAPN1 (0.48) | GRB2XIAPCAPN1CTSBOPRM1 | |
| SCHEMBL30543482 | 0.88 | GRB2 (0.52) | GRB2OPRM1 | |
| SCHEMBL30543490 | 0.88 | CMA1 (0.42) | GRB2XIAPKMT2ACAPN1CMA1 | |
| SCHEMBL29396765 | 0.85 | CAPN1 (0.52) | GRB2XIAPCAPN1CTSBSLC6A2 | |
| SCHEMBL30455247 | 0.85 | CAPN1 (0.52) | GRB2XIAPCAPN1CTSBSLC6A2 | |
| SCHEMBL29468766 | 0.84 | GRB2 (0.42) | GRB2XIAPKMT2ACAPN1CMA1 | |
| SCHEMBL29468837 | 0.83 | KMT2A (0.41) | GRB2KMT2ACMA1ITGB1ITGA4 | |
| SCHEMBL29641846 | 0.82 | GRB2 (0.51) | GRB2XIAPCAPN1CMA1CTSB | |
| SCHEMBL30028577 | 0.82 | KMT2A (0.45) | XIAPKMT2ACMA1ITGB1ITGA4 | |
| SCHEMBL30972553 | 0.80 | KMT2A (0.42) | KMT2ACMA1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622948-B2 | GLP-1/GIP dual agonists | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2026-05-12 | — | — | US | disclosed |
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| EP-4436991-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Sun Pharmaceutical Industries Limited (IN) | 2024-10-02 | — | — | EP | disclosed |
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2023-08-03 | — | — | US | disclosed |
| EP-4204440-A1 | GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023089594-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2023-05-25 | — | — | WO | disclosed |
| EP-4146248-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022079639-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | GRB2 524/4885XIAP 2144/4885KMT2A 1516/4885 |
| US-12622948-B2 | GLP-1/GIP dual agonists | GLP1R, GIPR, NPY4R | GRB2 1289/4885XIAP 4385/4885KMT2A 766/4885 |
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | GRB2 524/4885XIAP 2144/4885KMT2A 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.